ABSTRACT
We discuss a two-step model for the rise and decay of a new coronavirus (Severe Acute Respiratory Syndrome-CoV-2) first reported in December 2019, COVID-19. The first stage is well described by the same equation for turbulent flows, population growth and chaotic maps: a small number of infected d0 grows exponentially to a saturation value d∞. The typical growth λ time (aggressive spreading of the virus) is given by , where λ is the Lyapunov exponent.!After a time tcrit determined by social distancing and/or other measures, the spread decreases exponentially as for nuclear decays and non-chaotic maps. Some countries, like China, S. Korea and Italy are in this second stage while others including the USA are near the end of the growth stage. The model predicts 15,000 (±2,250) casualties for the Lombardy region (Italy) at the end of the spreading around May 10,2020. Without the quarantine, the casualties would have been more than 50,000, hundred days after the start of the pandemic. The data from the 50 US states are of very poor quality because of an extremely late and confused response to the pandemic, resulting unfortunately in a large number of casualties, more than 70,000 on May 6, 2020. S. Korea, notwithstanding the high population density (511/km2) and the closeness to China, responded best to the pandemic with 255 deceased as of May 6,2020.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
no external fundings
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
no IRB was needed
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
data available on request from the authors